Timeline
More in Healthcare
RTW-backed Yarrow Bioscience goes public via VYNE merger
RTW Biotech Opportunities booked a 3.7x return on its Yarrow investment after the thyroid disease biotech merged with VYNE Therapeutics and began trading on Nasdaq.